[Form 4] ADMA Biologics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ADMA Biologics (ADMA) Form 4 filing: CFO & Treasurer Brad L. Tade reported an automatic disposition of 7,123 common shares on 07/24/2025 using transaction code “F”, which indicates shares were withheld by the issuer solely to satisfy payroll-tax obligations triggered by restricted-stock-unit (RSU) vesting. The shares were valued at $17.31, an implied $123 k transaction value.

Following the tax withholding, Tade directly owns 239,419 shares. This total includes about 204,027 unvested RSUs granted in 2023-2025 that vest quarterly over four-year periods, plus 35,392 previously acquired shares. No derivative securities were bought or sold, and no open-market activity occurred.

The filing is routine, involves no cash proceeds to the insider, does not alter the company’s share count, and has limited market impact.

Positive

• CFO maintains a significant 239,419-share stake, preserving alignment with shareholder interests.
• Over 200,000 RSUs remain unvested, creating a long-term retention incentive tied to ADMA’s share performance.

Negative

• 7,123 shares were disposed (withheld for taxes), a minor reduction in insider exposure.

Insights

Financial Analyst

TL;DR: Routine tax-withholding sale; insider still heavily aligned with 239k shares—neutral market impact.

The F-code transaction shows mandatory share withholding rather than discretionary selling, removing any immediate bearish signal. With ~239k shares/RSUs remaining, the CFO retains substantial exposure to ADMA’s equity performance, which investors often view positively for alignment. Because the sale neither raises cash for the insider nor changes total shares outstanding, liquidity and valuation effects are negligible. I classify the filing as informational, not price-moving.

Corporate Governance Expert

TL;DR: Standard Section 16 compliance; no governance red flags detected.

The Form 4 meets all procedural requirements, clearly disclosing withholding shares for tax on RSU vesting. Such actions are customary and do not suggest strategic timing or intent to signal. Continued service-based vesting over four years strengthens retention incentives for the CFO. There are no indications of insider concern or upcoming negative developments. Overall governance impact is neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Tade Brad L.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2025		F		7,123(1)	D	$17.31	239,419(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

2. Includes, as of the transaction date, (i) 62,227 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 54,300 unvested RSUs granted on July 24, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 2) (iii) 37,500 unvested RSUs granted by the Company on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) (iv) 50,000 unvested RSUs, granted by the Company on June 26, 2023, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 35,392 shares acquired in open market purchases and pursuant to the vesting of RSUs after the withholding of shares to cover applicable taxes.

	/s/ Brad L. Tade, by Adam S. Grossman as Attorney-in-fact	07/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ADMA shares did the CFO dispose of on 07/24/2025?

The Form 4 reports 7,123 shares disposed to cover tax withholding.

At what price were the shares withheld?

The shares were valued at $17.31 each.

What is Brad L. Tade’s total beneficial ownership after the transaction?

He now directly beneficially owns 239,419 shares of ADMA common stock.

Does the filing include any open-market sales or derivative trades?

No. The only activity was share withholding for taxes; no open-market or derivative transactions were reported.

How many unvested RSUs does the CFO hold?

The footnotes disclose approximately 204,027 unvested RSUs from grants in 2023-2025.